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Abstract
Purpose:  The  purpose  of  this  study  was  to  evaluate  the  effect  of  pharmacologic  pupillary  dilata-
tion on  anterior  chamber  depth  (ACD)  and  anterior  chamber  angle  (ACA)  in  eyes  with  exfoliation
syndrome  (XFS).
Methods:  Thirty-six  eyes  of  36  patients  with  XFS  were  evaluated  with  slit-lamp  examination,
Goldmann  applanation  tonometry  and  ultrasound  biomicroscopy  (UBM)  under  standard  light
conditions.  Primary  outcome  parameters  were  deﬁned  as  the  change  in  ACD  and  ACA  measured
before and  40  min  after  instillation  of  a  single  drop  of  either  1%  cyclopentolate  (Group  I;  n  =  12),
2.5% phenylephrine  (Group  II;  n  =  12)  or  1%  tropicamide  (Group  III;  n  =  12).  Change  in  intraocular
pressure (IOP)  during  the  same  time  interval  was  included  as  a  secondary  outcome  measure.
Results: The  average  predilatation  ACD,  ACA  and  IOP  values  in  the  study  subjects  were
2.54 ±  0.40  mm,  27.9  ±  6.3◦ and  14.9  ±  3.1  mmHg,  respectively.  There  were  no  signiﬁcant  differ-
ences in  the  mean  age  (p  =  0.461),  the  female/male  ratio  (p  =  0.232),  baseline  ACD  (p  =  0.841),
ACA (p  =  0.761)  or  IOP  (p  =  0.070)  within  the  three  groups.  Differences  in  dilation  induced
changes  in  ACD  (p  =  0.108),  ACA  (p  =  0.636)  and  IOP  (p  =  0.160)  between  the  three  groups  were
not statistically  signiﬁcant.
Conclusion:  Pupillary  dilatation  with  a  single  drop  of  1.0%  cyclopentolate,  2.5%  phenylephrine
or 1%  tropicamide  is  not  associated  with  shallowing  of  the  anterior  chamber  or  narrowing  of
the ACA  in  patients  with  XFS  who  present  with  open  angles.
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reserved.
∗ Corresponding author at: Hacettepe Üniversitesi, Göz Hastalıkları Anabilim Dalı, Sıhhiye, 06100 Ankara, Turkey.
E-mail addresses: cmocan@hacettepe.edu.tr (M.C. Mocan), mirkec@isnet.net.tr (M. Irkec).
1 Associate Professor of Ophthalmology.
2 Resident in Ophthalmology.
3 Professor of Ophthalmology.
1888-4296/$ – see front matter © 2013 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
http://dx.doi.org/10.1016/j.optom.2013.05.001
52  M.C.  Mocan  et  al.
PALABRAS  CLAVE
Síndrome  de
exfoliación;
Profundidad  de  la
cámara  anterior;
Ángulo  de  la  cámara
anterior;
Biomicroscopia
ultrasónica;
Dilatación  de  la
pupila
Efecto  de  la  dilatación  farmacológica  de  la  pupila  sobre  los  parámetros  del  segmento
anterior  en  pacientes  con  síndrome  de  exfoliación
Resumen
Objetivo:  El  objetivo  de  este  estudio  fue  el  de  evaluar  el  efecto  de  la  dilatación  farmacológica
de la  pupila  sobre  la  profundidad  de  la  cámara  anterior  (PCA)  y  el  ángulo  de  la  cámara  anterior
(ACA) en  ojos  con  síndrome  de  exfoliación  (SXF).
Métodos:  Se  evaluaron  treinta  y  seis  ojos  de  36  pacientes  con  SXF  mediante  una  lámpara  de
hendidura,  tonometría  de  aplanación  de  Goldmann  y  biomicroscopia  ultrasónica  (BMU),  en
condiciones  de  iluminación  estándar.  Se  deﬁnieron  como  parámetros  de  medida  primarios  del
resultado a  los  cambios  de  PCA  y  ACA  medidos  con  anterioridad  y  a  los  40  minutos  de  la  insti-
lación de  una  única  gota  de  ciclopentolato  al  1%  (Grupo  I;  n  =  12),  fenilefrina  al  2,5%  (Grupo
II; n  =  12)  o  tropicamida  al  1%  (Grupo  III;  n  =  12).  Se  incluyó  el  cambio  de  la  presión  intraocular
(PIO) durante  el  mismo  intervalo  de  tiempo  como  medición  secundaria  del  resultado.
Resultados:  Los  valores  medios  de  PCA,  ACA  y  PIO  previos  a  la  dilatación  en  los  pacientes
del estudio  fueron  de  2,54  ±  0,40  mm,  27,9  ±  6,3◦ y  14,9  ±  3,1  mmHg,  respectivamente.  No
existieron  diferencias  en  cuanto  a  la  edad  media  (p  =  0,461),  el  ratio  hombre/mujer  (p  =  0,232),
PCA basal  (p  =  0,841),  ACA  (p  =  0,761)  o  PIO  (p  =  0,070)  dentro  de  estos  tres  grupos.  La  diferen-
cias en  los  cambios  inducidos  tras  la  dilatación  en  cuanto  a  PCA  (p  =  0,108),  ACA  (p  =  0,636)  y
PIO (p  =  0,160)  entre  los  tres  grupos  no  fueron  estadísticamente  signiﬁcativos.
Conclusión:  La  dilatación  de  la  pupila  con  una  única  gota  de  ciclopentolato  al  1%,  fenilefrina
al 2,5%  o  tropicamida  al  1%  no  está  asociada  a  una  disminución  signiﬁcativa  de  la  profundidad
de la  cámara  anterior  o  al  estrechamiento  de  la  ACA  en  los  pacientes  con  SXF  que  presentan
ángulos  abiertos.
©  2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
derechos reservados.
I
E
c
o
t
e
c
(
t
e
p
u
I
f
d
p
w
r
o
d
u
i
a
a
e
z
d
b
f
a
p
c
s
w
M
T
s
T
o
p
t
d
w
t
c
c
o
o
g
i
o
s
entroduction
xfoliation  syndrome  (XFS)  is  the  most  common  identiﬁable
ause  of  secondary  open-angle  glaucoma  with  a  prevalence
f  more  than  50%  of  cases  of  open-angle  glaucoma  in  cer-
ain  geographic  locations.1,2 Patients  with  XFS  need  to  be
valuated  on  a  regular  basis  for  the  detection  of  glau-
omatous  optic  neuropathy  as  elevated  intraocular  pressure
IOP)  may  result  in  a  rapidly  deteriorating  visual  function  in
hese  patients.1,3,4 Combined  with  an  older  age,  the  pres-
nce  of  XFS  increases  the  probability  of  observing  miotic
upils  during  clinical  evaluation  and  making  optic  disc  eval-
ations  difﬁcult  to  perform  without  pupillary  dilatation.5
n  clinical  practice,  pupillary  dilatation  is  commonly  per-
ormed  using  mydriatic  or  cycloplegic  drops.  Although  one
rop  of  short  acting  mydriatic  agent  such  as  2.5%  phenyle-
hrine  is  sufﬁcient  for  observing  the  posterior  pole  in  eyes
ith  light  colored  irides,  darker  brown-pigmented  eyes  may
equire  a  parasympatholytic  agent  such  as  1%  tropicamide
r  1%  cyclopentolate  for  adequate  dilatation.6 Pupillary
ilatation  is  not  without  its  own  risks  in  the  elderly  pop-
lation;  it  may  induce  an  episode  of  angle-closure  glaucoma
n  susceptible  individuals  who  have  certain  risk  factors  such
s  female  gender,  increased  age,  thickened  lens,  shallow
nterior  chamber  and  narrow  angle  conﬁguration.7 The  pres-
nce  of  XFS  may  compound  these  risk  factors  by  inducing
onular  laxity  with  resultant  forward  shift  of  the  iris-lens
iaphram  and  eventual  increase  in  the  degree  of  pupil
lock.1,8 In  addition,  narrow-angle  conﬁguration  is  more
requently  observed  in  subjects  with  XFS  as  compared  to
ge-matched  control  subjects.9,10
c
ﬁ
g
tThe  aim  of  this  study  was  to  test  the  hypothesis  that
upillary  dilatation  may  induce  narrowing  of  the  anterior
hamber  depth  (ACD)  and  anterior  chamber  angle  (ACA)  in
ubjects  with  XFS  who  present  with  clinically  normal  angle
idths.
ethods
he  study  was  designed  as  a cross-sectional,  observational
tudy  undertaken  at  a  single  university  based  hospital.  The
enets  of  the  Declaration  of  Helsinki  was  followed  through-
ut  the  study.  Informed  consent  was  obtained  from  all
atients  and  the  study  was  carried  out  with  approval  from
he  Institutional  Review  Board.  Patients  with  clinical  evi-
ence  of  XFS  were  included  this  study.  The  diagnosis  of  XFS
as  made  upon  identiﬁcation  of  ﬁbrillogranular  material  at
he  pupillary  ruff  and/or  the  presence  of  typical  anterior
apsular  appearance  deﬁned  by  the  presence  of  central  disc,
lear  intermediate  zone  and  peripheral  granular  zone  as
bserved  with  slit-lamp  biomicroscopy.  Clinical  assessment
f  ACA  width  was  made  using  the  van  Herick  technique11 and
onioscopy.  Only  subjects  with  brown  colored  iridiae  were
ncluded.  Exclusion  criteria  consisted  of  intraocular  pressure
f  >21  mmHg  on  at  least  >2  ofﬁce  evaluations,  ophthalmo-
copic  sign  of  glaucomatous  optic  nerve  cupping,  clinically
vident  narrow  angles  as  deﬁned  by  the  presence  of  anterior
hamber  depth  <1/2  of  corneal  thickness,  iris  bombe,  visual
eld  defects,  pseudophakia,  a  history  of  intraocular  surgery,
laucoma  or  posterior  segment  disease.  Patients  with  mild
o  moderate  grade  of  nuclear  sclerosis  were  not  excluded.
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Figure  1  (A)  Anterior  chamber  depth  (ACD)  was  determined  by  measuring  the  distance  between  the  posterior  surface  of  the
central cornea  and  the  most  central  portion  of  the  anterior  lens  capsule.  (B)  Anterior  chamber  angle  (ACA)  width  was  measured  as
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othe angle  formed  between  two  lines  coursing  parallel  to  the  a
posterior corneal  surface.
All  patients  underwent  complete  eye  evaluation  includ-
ing  slit-lamp  biomicroscopy,  gonioscopy  and  Goldmann
applanation  tonometry  (with  at  least  two  measurements  at
different  times  of  the  day)  and  UBM.  UBM  was  performed  by
a  single  observer  (MCM)  using  Ultrasound  Biomicroscopy  Plus
(Utah,  USA)  under  the  same  light  conditions.  ACD  was  mea-
sured  between  the  posterior  boundary  of  the  central  cornea
and  the  central  portion  of  the  anterior  lens  capsule  (Fig.  1A).
The  average  of  two  ACD  measurements  was  calculated.  The
ACA  width  was  deﬁned  as  the  angle  formed  by  a  line  con-
necting  the  inner  surface  of  the  peripheral  cornea  and  the
iris  root  and  a  line  joining  the  iris  root  and  the  peripheral
anterior  iris  plane  (Fig.  1B).  The  average  of  nasal  and  tempo-
ral  ACA  measurements  was  calculated.  Measurements  were
performed  with  the  caliper  included  in  the  UBM  software.
Patients  were  randomized  to  receive  one  drop  of  either  1%
cyclopentolate  (Group  I;  n  =  12),  2.5%  phenylephrine  (Group
II;  n  =  12)  or  1%  tropicamide  (Group  III;  n  =  12)  in  the  eye
with  XFS.  Patients  underwent  repeat  UBM  evaluations  and
IOP  determinations  40  min  following  the  instillation  of  top-
ical  drops.  This  time  period  was  chosen  to  represent  the
instant  at  which  maximum  pharmacologic  effect  of  the
dilating  agents  would  be  observed.12 The  maximum  mydri-
atic  effect  of  1.0%  cyclopentolate,  2.5%  phenylephrine  and
1%  tropicamide  are  reported  to  range  between  30--60  min,
20--40  min  and  15--60  min,  respectively.12 The  primary  out-
come  measures  were  the  changes  in  ACD  and  ACA  following
pupillary  dilatation.  The  secondary  outcome  measure  was
the  change  in  IOP  between  the  same  time  points  when
anterior  chamber  parameters  were  evaluated.  Patients  were
re-evaluated  24--48  h  following  pharmacologic  dilatation  for
signs  of  increased  intraocular  pressure.
The  differences  between  preinstillation  and  postinstilla-
tion  ACD  [ACD],  ACA  [ACA]  and  IOP  [IOP]  parameters
were  calculated  for  each  subject.  Statistical  evaluations
were  performed  using  SPSS  ver.  18.0  (Chicago,  USA)
software.  Chi-square  test  was  used  to  evaluate  gender  distri-
bution  within  groups.  The  differences  between  predilatation
and  postdilatation  values  for  ACD,  ACA  and  IOP  in  all  sub-
jects  were  evaluated  with  the  Wilcoxon  signed  rank  test.
The  Kruskal--Wallis  one-way  analysis  of  variance  test  was
employed  to  compare  [ACD],  [ACA]  AND  [IOP]  between
Group  I,  Group  II  and  Group  III  subjects.  Mann  Whitney  U  test
b
s
f
Ior  surface  of  the  peripheral  iris  and  peripheral  portion  of  the
as  used  to  compare  ACD,  ACA  and  IOP  values  of  female  vs.
ale  subjects.  Spearman’s  correlation  test  was  used  to  eval-
ate  the  strength  of  association  between  predilatation  and
ostdilatation  ACD,  ACA  and  IOP  parameters.  A  p  value  of
ess  than  0.05  was  considered  signiﬁcant.
esults
hirty-six  eyes  of  36  patients  (20  females,  16  males)  were
ncluded  in  the  study.  The  mean  age  of  the  study  subjects
as  69.4  ±  7.4  years  (range  =  47--80  years).  The  average
redilatation  ACD,  ACA  and  IOP  values  of  all  study  subjects
ere  2.54  ±  0.40  mm,  27.9  ±  6.3◦ and  14.9  ±  3.1  mmHg,
espectively.  There  were  no  signiﬁcant  differences  in  either
he  age  parameter  (p  =  0.461),  the  female/male  ratio
p  =  0.232),  baseline  ACD  (p  = 0.841),  ACA  (p  =  0.761)  or  IOP
p  =  0.070)  between  the  three  groups.  The  pupils  of  all
ubjects  were  observed  to  be  dilated  more  than  5  mm
nd  were  nonreactive  to  light  following  application  of
ydriatic/cycloplegic  drops.  For  all  (n  =  36)  subjects,  the
ean  changes  in  ACD  (0.03  ±  0.08  mm;  p  =  0.109)  and  ACA
0.60  ±  4.40◦; p  =  0.520)  following  dilatation  was  not  found
o  be  statistically  signiﬁcant.  The  mean  values  related  to
CA,  ACD  and  IOP  parameters  before  and  after  pupillary
ilatation  for  the  three  groups  are  shown  in  Table  1.  Com-
aring  the  three  groups,  dilatation  induced  changes  in  ACD
ACD] (p  =  0.108),  ACA  [ACA]  (p  =  0.636)  and  IOP  [IOP]
p  =  0.160)  were  not  signiﬁcantly  different  as  evaluated  with
he  Kruskal--Wallis  one-way  analysis  of  variance  test.  In  addi-
ion,  [ACD],  [ACA]  and  [IOP]  of  subjects  who  received
ycloplegic  drops  (Groups  I  and  III)  were  not  signiﬁcantly
ifferent  (p  = 0.052  for  [ACD],  p  =  0.481  for  [ACA]  and
 =  0.283  for  [IOP])  than  subjects  who  received  mydriatic
rops  (Group  II).
None  of  the  eyes  in  any  group  developed  >10◦ of  angle
arrowing  following  pupillary  dilatation  and  only  three  eyes
n  group  I,  and  one  eye  in  groups  II&III  had  between  5◦ and
0◦ of  angle  narrowing  following  dilatation.  In  addition,  only
ne  eye  in  group  II  developed  >5%  (5.85%)  of  anterior  cham-
er  shallowing.  Although  there  appeared  to  be  a  statistically
igniﬁcant  mean  IOP  change  of  1.0  ±  1.2  mmHg  (p  <  0.001)
or  all  subjects  following  dilatation,  no  signiﬁcant  intergroup
OP  differences  were  detected  (p  =  0.160).
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Table  2  Correlation  analysis  of  anterior  chamber  depth,
anterior  chamber  angle  and  intraocular  pressure  before  and
after pupillary  dilatation  as  evaluated  with  Spearman’s  cor-
relation  analysis.
Parameters  Correlation  coefﬁcient
(rho)
p
ACDpre −  ACDpost 0.981  <0.001
ACApre −  ACApost 0.820  <0.001
IOPpre −  IOPpost 0.883  <0.001
ACDpre: predilatation anterior chamber depth; ACDpost: postdi-
latation anterior chamber depth; ACApre: predilatation anterior
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achamber angle; ACApost: postdilatation anterior chamber angle;
IOPpre: predilatation intraocular pressure; IOPpost: postdilata-
tion intraocular pressure.
The  mean  ACD  and  ACA  measurements  of  male  subjects
2.63  ±  0.44  mm,  28.4  ±  7.2◦) were  not  signiﬁcantly  differ-
nt  when  compared  to  those  of  female  (2.47  ±  0.35  mm,
7.5  ±  5.7◦)  subjects  (p  =  0.233,  p  =  0.726).
Spearman’s  correlation  analysis  did  not  reveal  a  sig-
iﬁcant  association  of  subject  age  with  predilatation  ACD
r  =  −0.150;  p  =  0.382),  ACA  (r  =  −0.06;  p  =  0.743)  or  IOP
r  =  −0.071;  p  =  0.683).  However,  predilatation  and  postdi-
atation  values  for  ACD,  ACA  and  IOP  were  found  to  be
trongly  correlated  (Table  2).
The  reliability  and  repeatability  of  the  ACA  and  ACD
arameters  as  obtained  with  UBM  were  found  to  be  high;
he  intraclass  correlation  coefﬁcient  and  95%  conﬁdence
ntervals  (CI)  of  the  ACD  and  ACA  parameters  were  0.999
95%  CI:  0.998--1.000)  and  0.988  (95%  CI:  0.967  and  0.996),
espectively.
iscussion
harmacologic  pupillary  dilatation  has  the  potential  to  pre-
ipitate  an  acute  attack  of  angle-closure  glaucoma  by
reating  a  mid-dilated  pupil  conﬁguration  and  pupillary
lock.13 This  phenomenon  is  more  likely  in  the  setting  of
arrow  angles  or  in  eyes  in  which  forward  lens  displacement
ccurs.  The  latter  group  includes  eyes  with  ectopia  lentis
econdary  to  zonular  dehiscence.  Angle  closure  in  eyes  with
FS  may  develop  due  to  the  combination  of  factors  includ-
ng  forward  displacement  of  the  lens-iris  diaphram  related
o  zonular  weakness,  lens  thickening,  formation  of  poste-
ior  synechiae  and  a  rigid-thickened  iris.8 In  the  current
tudy,  none  of  the  eyes  in  any  group  developed  >10◦ of  angle
arrowing  following  pupillary  dilatation,  suggesting  that  a
ingle  drop  of  commercially  available  dilating  agents  is  safe
or  diagnostic  pupillary  dilatation  in  patients  with  XFS.  This
nding  may  be  explained  on  the  basis  that  one  drop  of  top-
cal  dilating  medications  used  in  the  study  is  not  sufﬁcient
o  induce  alterations  of  the  anterior  chamber  depth  in  XFS.
ur  results  are  representative  of  a  subset  of  XFS  patients
ith  clinically  open  angles  as  evaluated  with  the  van  Herick
ethod.
There  exists  a  subset  of  patients  with  exfoliation  syn-rome  who  present  with  clinically  overt  narrow  angles
ith  or  without  iris  bombe.8 In  a  recent  study  by
amji  et  al.,8;  the  ACD  of  XFS  subjects  with  occlud-
ble  angles  (1.88  ±  0.07  mm)  was  lower  compared  to  those
ent
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with  open-angle  conﬁguration  (2.37  ±  0.05  mm).  The  aver-
age  predilatation  ACD  and  ACA  values  in  the  study  subjects
of  our  study  were  2.54  ±  0.40  mm  and  27.9  ±  6.3◦,  respec-
tively,  more  closely  resembling  the  open-angle  XFS  group
described  in  the  study  by  Damji  et  al.8 In  eyes  with  XFS,
ACD  may  be  an  important  parameter  to  evaluate  the  risk  of
angle  closure  and  the  presence  of  zonular  weakness.8 We
did  not  include  subjects  with  clinically  overt  narrow  angles
in  the  current  study  in  whom  angle  closure  could  have  been
precipitated  with  pupillary  dilatation.
IOP  elevations  are  reported  in  patients  with  glaucoma
following  pupillary  dilatation.14 The  suggested  mechanisms
that  induce  IOP  elevations  in  glaucomatous  eyes  are  pig-
ment  liberation  into  the  anterior  chamber  with  subsequent
blockage  of  trabecular  meshwork  and  decreased  contrac-
tility  of  ciliary  muscle  on  the  trabecular  meshwork  leading
to  decreased  aqueous  outﬂow.14 The  rise  in  IOP  is  observed
within  45--120  min  following  instillation  of  dilating  drops  and
may  remain  elevated  for  4--6  h.14 Accordingly,  pigment  liber-
ation  into  the  anterior  chamber  is  observed  in  XFS  and  may
be  accentuated  with  pupillary  dilatation.1
In  the  current  study,  postdilatation  ACD,  ACA  and  IOP
measurements  were  strongly  correlated  with  their  respec-
tive  predilatation  values  (Table  2).  This  observation  may
have  a  potential  value  in  making  an  estimate  regarding
anterior  chamber  parameters  following  pupillary  dilatation.
Although  increasing  age  is  associated  with  angle-closure
glaucoma,15 it  does  not  appear  to  be  associated  with  angle
width  and  anterior  chamber  depth  in  eyes  with  XFS.
A  drawback  of  this  study  is  that  the  anterior  segment
parameters  of  all  subjects  were  evaluated  only  in  the  supine
position  due  to  the  setup  of  the  immersion  lens  of  the  UBM.
Evaluation  of  ACD  and  ACA  in  the  supine  vs.  prone  posi-
tion  may  be  especially  relevant  in  the  presence  of  zonular
weakness  associated  with  XFS  as  measurements  obtained  in
the  supine  position  may  not  reﬂect  the  physiological  state
of  eyes  with  XFS.  ACD,  ACA  and  IOP  measurements  were
recorded  only  at  the  end  of  a  40-min  interval;  late  measure-
ments  were  not  made.  Therefore  the  protracted  course  of
anterior  chamber  parameters  cannot  be  inferred  from  the
results  of  this  study.  The  pigment  liberation  and  IOP  rise
is  reported  to  reach  its  maximum  values  at  1--2  h  following
pupillary  dilatation.16,17 IOP  rise  of  1.0  mmHg  was  observed
in  patients  with  XFS  as  early  as  40  min  post-dilatation;  this
may  represent  the  beginning  of  the  IOP  rise  associated  with
pigment  liberation.  However,  patients  were  re-evaluated
24--48  h  following  pharmacologic  dilatation  and  no  reports
of  ocular  pain  or  blurring  of  vision  was  obtained  from  the
subjects.  Even  though  this  study  did  not  include  a  sample
control  group,  the  results  of  a  recent  study  by  Doganay  et  al.
demonstrated  that  ACD  and  ACA  are  similar  between  sub-
jects  with  XFS  and  healthy  individuals.18 One  ﬁnal  drawback
of  the  study  was  that  the  three  dilating  drops  could  not
be  administered  sequentially  to  all  participants  in  differ-
ent  days  due  to  the  fact  that  several  patients  enrolled  in
the  study  lived  in  remote  locations  and  could  not  return  for
repeat  evaluations.
Narrow  angle  conﬁguration  in  the  setting  of  XFS  is  not
uncommon;  according  to  a  previous  report  nearly  one  in
three  patients  with  XFS  have  narrow  or  occludable  angles  as
veriﬁed  with  gonioscopic  evaluation.9 As  suggested  by  the
ﬁndings  of  Damji  et  al.,8 eyes  with  XFS  should  be  vigilantly parameters  55
valuated  for  the  presence  of  occludable  angles  using  the
an  Herick  technique  followed  by  conﬁrmatory  compression
onioscopy  if  the  corneal  thickness/anterior  chamber  depth
atio  is  <0.25.  In  these  cases,  caution  is  always  advised  in
erforming  pupillary  dilatations  in  eyes  with  or  without  XFS.
onetheless,  pharmacologic  pupillary  dilatation  for  diagnos-
ic  purposes  far  outweigh  the  risk  of  inducing  angle  closure
laucoma.19 The  results  of  our  study  suggest  that  pupillary
ilatation  with  a  single  drop  of  1.0%  cyclopentolate,  2.5%
henylephrine  or  1%  tropicamide  is  not  associated  with  nar-
owing  of  the  anterior  chamber  angle  in  patients  with  XFS
ho  have  clinically  open  normal  angle  at  presentation.
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